Profluent Bio vs Nuvig Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

Nuvig Therapeutics leads in AI visibility (54 vs 36)
Profluent Bio logo

Profluent Bio

EmergingBiotechnology

AI Protein Design

AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; raised $35M developing novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space beyond what evolution has produced.

AI VisibilityBeta
Overall Score
D36
Category Rank
#94 of 198
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
40
Perplexity
33
Gemini
37

About

Profluent Bio is an AI protein design company founded in 2022 by former Meta AI researcher Ali Madani, raising $35M in seed and Series A funding. The company trains large generative models on biological sequence data to design novel proteins with specific structural and functional properties, analogous to how large language models generate text. Profluent made scientific history in 2024 by publishing OpenCRISPR-1, the first gene editor designed entirely by AI rather than adapted from natural organisms, which the company released open source for non-commercial research. The platform enables design of novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space far beyond what evolution has produced. Profluent works with pharmaceutical and agricultural biotechnology companies that need custom protein tools for research and therapeutic development. The company represents a fundamental advance in moving protein engineering from directed evolution and rational design toward generative AI-driven discovery.

Full profile
Nuvig Therapeutics logo

Nuvig Therapeutics

ChallengerLife Sciences & BioTech

Immunology & Autoimmune Therapeutics

Nuvig Therapeutics develops first-in-class Fc-fragment immunomodulators targeting endogenous regulatory pathways to treat autoimmune diseases without broad immune suppression.

AI VisibilityBeta
Overall Score
C54
Category Rank
#26 of 198
AI Consensus
87%
Trend
stable
Per Platform
ChatGPT
55
Perplexity
59
Gemini
56

About

Nuvig Therapeutics is a privately held biotechnology company developing next-generation immunomodulatory therapies for patients with chronic inflammatory and autoimmune diseases. Its lead candidate, NVG-2089, is a first-in-class recombinant Fc fragment engineered to bind type II Fc receptors and engage an endogenous regulatory mechanism that restores immune balance without the broad immunosuppression associated with existing treatments.

Full profile

AI Visibility Head-to-Head

36
Overall Score
54
#94
Category Rank
#26
79
AI Consensus
87
stable
Trend
stable
40
ChatGPT
55
33
Perplexity
59
37
Gemini
56
32
Claude
55
38
Grok
59

Key Details

Category
AI Protein Design
Immunology & Autoimmune Therapeutics
Tier
Emerging
Challenger
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Profluent Bio
AI Protein Design

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.